GOLD Classifications, COPD Hospitalization, and All-Cause Mortality in Chronic Obstructive Pulmonary Disease: The HUNT Study.
ABCD groups
AUC
COPD hospitalization
GOLD grades
area under curve
mortality
Journal
International journal of chronic obstructive pulmonary disease
ISSN: 1178-2005
Titre abrégé: Int J Chron Obstruct Pulmon Dis
Pays: New Zealand
ID NLM: 101273481
Informations de publication
Date de publication:
2020
2020
Historique:
received:
28
08
2019
accepted:
09
01
2020
entrez:
27
2
2020
pubmed:
27
2
2020
medline:
10
2
2021
Statut:
epublish
Résumé
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) has published three classifications of COPD from 2007 to 2017. No studies have investigated the ability of these classifications to predict COPD-related hospitalizations. We aimed to compare the discrimination ability of the GOLD 2007, 2011, and 2017 classifications to predict COPD hospitalization and all-cause mortality. We followed 1300 participants with COPD aged ≥40 years who participated in the HUNT Study (1995-1997) through to December 31, 2015. Survival analysis and time-dependent area under receiver operating characteristics curves (AUC) were used to compare the discrimination abilities of the GOLD classifications. Of the 1300 participants, 522 were hospitalized due to COPD and 896 died over 20.4 years of follow-up. In adjusted models, worsening GOLD 2007, GOLD 2011, or GOLD 2017 categories were associated with higher hazards for COPD hospitalization and all-cause mortality, except for the GOLD 2017 classification and all-cause mortality (p The GOLD 2007 classification was better than the GOLD 2011 and 2017 classifications at predicting COPD hospitalization and all-cause mortality.
Identifiants
pubmed: 32099347
doi: 10.2147/COPD.S228958
pii: 228958
pmc: PMC6999582
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
225-233Informations de copyright
© 2020 Bhatta et al.
Déclaration de conflit d'intérêts
LB reports personal fees for presenting the abstract of this study at Nordic Respiratory Science Forum (NRSF) organized by AstraZeneca in 2019. The authors report no other conflicts of interest in this work.
Références
Eur Respir J. 2016 Dec;48(6):1602-1611
pubmed: 27824594
Eur Respir J. 2010 Apr;35(4):873-82
pubmed: 19741033
Lancet Respir Med. 2015 Jun;3(6):443-50
pubmed: 25995071
Biometrics. 2005 Mar;61(1):92-105
pubmed: 15737082
Int J Chron Obstruct Pulmon Dis. 2018 Oct 18;13:3425-3433
pubmed: 30425472
Am J Respir Crit Care Med. 2012 Nov 15;186(10):975-81
pubmed: 22997207
Biometrics. 2010 Dec;66(4):999-1011
pubmed: 20070296
BMC Med Res Methodol. 2017 Apr 7;17(1):53
pubmed: 28388943
J Formos Med Assoc. 2015 Dec;114(12):1258-66
pubmed: 25676673
Am J Respir Crit Care Med. 2013 Jul 1;188(1):51-9
pubmed: 23590268
Int J Tuberc Lung Dis. 2000 Jan;4(1):83-90
pubmed: 10654649
Respir Med. 2018 May;138:50-56
pubmed: 29724393
Thorax. 2013 Oct;68(10):914-21
pubmed: 23611880
COPD. 2018 Feb;15(1):21-26
pubmed: 29161163
Lancet Respir Med. 2018 Mar;6(3):204-212
pubmed: 29331311
Int J Epidemiol. 2013 Aug;42(4):968-77
pubmed: 22879362
J Thorac Oncol. 2010 Sep;5(9):1315-6
pubmed: 20736804
Eur Respir J. 2015 May;45(5):1283-92
pubmed: 25537554
Chronic Obstr Pulm Dis. 2019 Jan 10;6(1):64-73
pubmed: 30775425
Chest. 1988 Mar;93(3):580-6
pubmed: 3342669
Eur Respir J Suppl. 1993 Mar;16:5-40
pubmed: 8499054
Am J Respir Crit Care Med. 1995 Sep;152(3):1107-36
pubmed: 7663792
Am J Respir Crit Care Med. 2018 Feb 15;197(4):463-469
pubmed: 29099607
Med Decis Making. 2018 Nov;38(8):904-916
pubmed: 30319014
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
Int J Chron Obstruct Pulmon Dis. 2017 May 18;12:1491-1501
pubmed: 28553101
Clin Respir J. 2012 Oct;6(4):208-14
pubmed: 22906068